Endovascular tools to assist in the recanalization of acutely occluded intracranial vessels and restoration of cerebral blood flow are rapidly evolving and expanding. Non-randomized trials suggest that these intra-arterial (IA) devices can increase the likelihood of recanalization of large artery occlusions compared to intravenous thrombolysis alone [1] [2] [3] [4] [5] [6] [7] [8] . Numerous studies have demonstrated an association between recanalization and improved functional outcome 9 . This increased recanalization rate with endovascular therapy, however, comes with a potential increased risk of a serious adverse event such as intracranial hemorrhage. A direct comparison of the outcome of intravenous and intra-arterial (or combined intravenous and intra-arterial) therapy awaits the completion of large randomized controlled trials 10, 11 .
and balloon angioplasty are tools that are widely available at all neurointerventional centers. Intra-arterial thrombolysis has been demonstrated to improve the outcome of patients with acute stroke due to middle cerebral artery (MCA) occlusion if administered within six hours of symptoms onset 12, 13 . Few studies, however, have specifically examined the safety and efficacy of angioplasty as primary or adjunctive therapy in acute stroke [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Since angioplasty is not permitted in the treatment protocols of ongoing randomized interventional acute stroke trials 10, 11 , further evidence of the utility of this treatment modality in acute stroke will depend on analysis of nonrandomized data sources.
We have previously reported our initial experience using clot angioplasty for acute anterior circulation stroke 20 . The purpose of this study was to determine whether an endovascular strategy that utilizes angioplasty is a safe and effective approach for the treatment of acute stroke due to large vessel occlusion.
PATIENTS AND METHODS
This study was approved by the institutional research ethics board. We retrospectively reviewed 70 consecutive patients presenting with acute ischemic stroke due to large vessel occlusion and treated with endovascular therapy from June 2002 to September 2009 at a single centre. Baseline clinical, imaging and angiographic information was retrospectively collected (Table 1) . Disability was assessed using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS). A mRS score of 0-2 at one month was considered a favorable outcome. Three month follow-up data was incomplete and therefore not provided.
Patients were initially considered for intravenous thrombolysis as per the institutional protocol. They were then considered for endovascular therapy if they: (a) had a disabling neurological deficit (b) had a non-contrast head computed tomogram (CT) without evidence of extensive early ischemic changes (c) had a CT angiography demonstrating a large proximal vessel occlusion (ICA/M1/M2/vertebrobasilar) (d) could be transferred to the angiography suite for initiation of endovascular therapy within 4.5 hours of symptom onset or longer for patients with posterior circulation ischemia (considered on an individual basis). There was no age limitation.
Endovascular procedure
Patients underwent selective angiography and endovascular treatment under conscious sedation and using local analgesia. General anesthesia was only utilized if there was concern about a patient's respiratory or cardiovascular status (n=14).
A 2000 unit bolus of heparin was administered immediately after femoral sheath insertion. Angiography was performed via a guiding catheter positioned in the proximal internal carotid artery (ICA) or vertebral artery to demonstrate the proximal extent of occlusive thrombus and assess progress. Microcatheter contrast injections distal to the occlusive thrombus were minimized given their association with an increased risk of intracranial hemorrhage 26 .
The precise endovascular treatment protocol utilized (tools and sequence of use) was at the discretion of the treating neurointerventionalist, but included one or more of the following modalities: intra-arterial lytics (tissue plasminogen activator (tPA) or abciximab), microwire/microcatheter clot maceration, mechanical retriever (MERCI, Concentric Medical, Mountain View, CA), balloon angioplasty or stenting. Stent retrievers and thromboaspiration devices were not utilized in the treatment of patients in this cohort. The initial modality utilized was either CAD, coronary artery disease; PVD, peripheral vascular disease; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; pcASPECTS, posterior circulation Alberta Stroke Program Early CT Score. * Four baseline scans were not available for review. ** No patients had a baseline ASPECTS or pcASPECTS <6. intra-arterial tPA administration or mechanical thrombectomy/ retrieval in patients with appropriate vascular anatomy. Intraarterial lytics were administered via a microcatheter positioned at the proximal edge or within the occlusive thrombus. The median intra-arterial tPA and abciximab doses given were 11 mg and 7 mg, respectively. Clot maceration was often performed by carefully and repeatedly traversing the thrombus with microwire and microcatheter. Angioplasty was generally considered only after inadequate or failed recanalization with lytic agent, mechanical thrombectomy or both. In four patients, angioplasty was the only endovascular modality utilized. Angioplasty was performed using 4 mm x 10 or 20 mm HyperGlide or 4 mm x 7 mm HyperForm balloons (ev3, Irvine, CA), sized according to clot location and estimated vessel diameter (M1 or M2 segment or basilar artery). Multiple slow and gentle inflations of 10-20 second duration were performed under roadmap guidance, repositioning the balloon along the occluded segment between inflations.
The procedure was terminated if recanalization was achieved, the elapsed time from onset of symptoms was greater than six hours (or longer for patients with posterior circulation ischemia, 12 hours being the longest in one patient) or due to perceived treatment futility. In patients with severe proximal ICA or vertebrobasilar stenosis, stents were placed only if distal flow was perceived to be inadequate and there was felt to be an elevated risk of re-thrombosis. Dual antiplatelet therapy was administered during procedures where stents were deployed.
Imaging
Baseline non-contrast CT head (NCCT) images (or magnetic resonance imaging (MRI) diffusion weighted images when available) were reviewed (MB, MA) for determination of the extent of baseline early ischemic change quantified using the ASPECTS (anterior circulation) 27 . The computed tomogram angiography (CTA) sources images of patients with vertebrobasilar ischemia were assessed for determination of pcASPECTS score 28 . The site of arterial occlusion (ICA, M1, M2, M1/M2, ICA/M1 and vertebrobasilar) was determined by reviewing CTA angiograms of the head and neck (MB, MA). Pre-and post-endovascular treatment angiograms were reviewed (MB, MA) and recanalization was graded according to the Thrombolysis in Cerebral Infarction (TICI) grading system: Grade 0: no perfusion, Grade 1: minimal perfusion, Grade 2: partial perfusion, Grade 3: complete perfusion 29 . Recanalization was defined as a TICI 2-3 and no recanalization was considered as a TICI 0-1.
Follow-up NCCT obtained 24 hours after treatment were reviewed for evidence of hemorrhagic transformation and graded according to the ECASS classification: HI-1 (small petechiae); HI-2 (confluent petechiae); PH-1 (hematoma in <30% of the infarcted area, with a mild space-occupying effect); and PH-2 (hematoma in >30% of the infarcted area, with a significant space-occupying effect) 30 . Any subarachnoid or intraventricular hemorrhage was graded as PH-2. Symptomatic intracranial hemorrhage (sICH) was defined as a 4 point or greater deterioration of NIHSS status in the first 24 hours after intraarterial therapy attributable to a hemorrhage seen on the followup CT scan.
Statistical analysis
Statistical analysis was performed using descriptive statistics and Student t distribution for paired samples. A two-tailed p<0.05 was considered significant. Direct statistical comparisons between treatment groups (angioplasty and no angioplasty) was not performed since groups were not randomly selected and treatment group allocation was dependent on findings at the time of angiography and treating physician preference.
RESULTS

Baseline characteristics
Baseline clinical information for patients that received endovascular acute stroke therapy is presented in Tables 1 and 2 (n=70). In patients that received angioplasty as a component of their endovascular intervention (n=35), the mean age was 65 with a median baseline NIHSS=15. Twenty seven (27/35, 77%) patients had an anterior circulation stroke and 8/35 (23%) a posterior circulation event. The site of arterial occlusion was at the M1 segment in 11 patients, M1/M2 in 3, ICA/M1 in 13 (including tandem and T-occlusions) and vertebrobasilar in 8 patients (Table 2 ). Median baseline ASPECTS was 9 for patients with anterior circulation ischemia and median pcASPECTS was 8 for patients with vertebrobasilar ischemia. Intravenous tPA was administered to 46% (16/35) of patients with median time from symptom onset to IV tPA administration of two hours. Nineteen patients were outside the time window for IV tPA administration or had contraindications to systemic pharmacological thrombolysis.
Endovascular treatment
Median time from symptom onset to endovascular therapy was four hours (Table 2) . Angioplasty was the only endovascular tool used in four patients (4/35, 11%). Balloons were used in combination with other interventional tools in 31/35 patients (89%). Intra-arterial lytic agents (tPA, abciximab or both) were co-administered before or after angioplasty in 27 patients. In six patients mechanical thrombectomy (MERCI retriever) was attempted prior to angioplasty. Angioplasty was the final or only modality utilized in 19/35 (54%). Eight patients had three or more endovascular modalities used in the course of treatment and among these, angioplasty was the final modality used in only one patient. After intracranial vessel recanalization was complete, a stent was placed to improve distal flow in seven patients with a severe residual stenosis of the cervical internal carotid (4/7) or vertebrobasilar (3/7) arteries.
Recanalization
The overall recanalization rate of acute arterial occlusions after endovascular therapy was 59% (41/70). In patients where angioplasty was used as one step of the endovascular protocol, recanalization was achieved in 23/35 (66%). Thrombolysis in Cerebral Infarction (TICI) 2-3 flow was achieved in 20 of these 23 patients after the angioplasty step alone. Median time from symptom onset to recanalization was six hours.
Intracranial hemorrhage
Symptomatic intracerebral hemorrhage occurred in 2/35 (6%) patients in the angioplasty group (Table 3) . In one patient, angioplasty was combined with intra-arterial tPA and in one patient mechanical retrieval with the MERCI device was attempted prior to angioplasty. The incidence of sICH was similar in patients that had not received angioplasty at any point during the endovascular treatment protocol (2/35, 6%) ( Table 3) . No arterial dissections or ruptures were observed in patients treated with angioplasty.
Clinical outcome
The median NIHSS at baseline was 15, 11 at 24 hours and 7 at one month. In the angioplasty group, a favorable clinical outcome (mRS 0-2) was achieved in 7/35 (20%) patients at 24 hours and 12/35 (34%) patients at one month of follow-up (Table  3 ). In the angioplasty group, recanalization was strongly associated with a favorable outcome (p<0.002). In patients with vessel recanalization, 52% (12/23 patients) had a favorable outcome at one month. In contrast, 0/12 patients with persistent large vessel occlusion at the end of treatment had a favorable outcome at one month. A similar correlation of recanalization with good outcome was seen in the non-angioplasty group, with 11/18 (61%) patients that recanalized achieving a good outcome compared to 2/17 (12%) patients that did not recanalize (p=0.03). Sixteen patients (16/35, 46%) in the angioplasty group were discharged home or to stroke rehabilitation (Table 3 ). The overall mortality rate in this group was 9/35 (26%) at 30 days.
DISCUSSION
The ideal endovascular tool to assist in recanalization of acutely occluded vessels should be easy to use, rapidly positioned into place and safely and consistently achieve a high rate of vessel recanalization. Unfortunately, no single intra-arterial device developed to date meets all these criteria. A multimodal treatment strategy is necessary, tailored to each individual patient and based on operator familiarity and tool availability. Newer tools such as the latest iteration of mechanical and stent retrievers or thromboaspiration devices are not universally available at all tertiary stroke centers due to cost or lack of regulatory approval 2, [6] [7] [8] . In contrast, angioplasty is widely available in most neurointerventional centers and balloons can be rapidly prepared and positioned into place. In our cohort, angioplasty used alone or in combination with other modalities was safe with a low sICH rate of 6%. Partial or complete vessel recanalization was achieved in 66% of patients and in these patients 87% (20/23 patients) recanalized immediately after angioplasty.
The rates of recanalization and sICH observed in our cohort of patients treated with angioplasty are similar to those reported previously. Ueda et al reported recanalization in 11/13 patients with one asymptomatic petechial hemorrhage in patients treated with angioplasty and intra-arterial thrombolytic 14, 15 . In another small series, recanalization occurred in 5/9 patients with one hemorrhage 16 . Percutaneous angioplasty in combination with intra-arterial thrombolysis resulted in partial or complete recanalization in 91% (31/34) of patients, at the expense of development of three small and one massive intracranial hemorrhages 18 . Recanalization rates were 75%, 90.9% and 91.6% in three additional small case series in patients treated with angioplasty, in conjunction with other endovascular modalities, with no symptomatic intracerebral hemorrhages reported [20] [21] [22] .
Reported rates of recanalization in acute stroke trials evaluating various neuro-interventional tools include: 66% with intraarterial urokinase 12 , 48% with the MERCI mechanical retriever alone 3 , 68% with the mechanical retriever in combination with thrombolytics 3 , 80% with thromboaspiration 6 and as high as 90% with stent retrievers 8 . Some potential explanations for the variation in reported rates of recanalization aside from device differences alone include: differences in clot location, extent and composition and time windows for endovascular therapy. None of the patients with anterior circulation stroke in our cohort were treated beyond six hours IV, intravenous; IA, intra-arterial; tPA, Tissue plasminogen activator; ICA, internal carotid artery; M1 or M2, proximal middle cerebral artery segments; ER, emergency room. * Including tandem and T-occlusions. ** Four patients had angioplasty alone. *** One patient had a stent placed in a proximal vertebral artery. A recent meta-analysis of 33 studies reporting recanalization and functional outcome after acute stroke, regardless of treatment received, demonstrated that vessel recanalization correlated strongly with outcome 9 . A favorable outcome (mRS 0-2) was achieved in 325/559 (58.1%) patients that recanalized versus 109/439 (24.8%) patients that did not recanalize (OR 4.43, 95% CI 3.32-5.91). We found an equally strong correlation of outcome with recanalization with 52% of recanalizers in the angioplasty group having a favorable outcome vs. 0% of nonrecanalizers (p=0.002). Similar observations have been made in other interventional acute stroke case series and trials 30, 31 . In the PROACT II study, the rate of recanalization was 66% in the endovascular group with 40% achieving a good clinical outcome compared to only 18% recanalization in the placebo group with 25% achieving good outcome 12 . The ratio of good clinical outcome in recanalizers vs. non-recanalizers in non-randomized trials was: IMS I-II 45.6% / 6.9% 1,2 MERCI I 46% / 10.4% 3 , Multi MERCI 49.1% / 9.6% 3 , Penumbra 29% / 9% 6 . Time to recanalization is also likely be an important factor with the probability of a good clinical outcome decreasing as time to angiographic recanalization increases 32 . In addition, although not routinely utilized, 14 patients in our cohort required intubation and mechanical ventilation due to respiratory or cardiovascular compromise. General anesthesia may be associated with worse outcome after interventional stroke therapy 33, 34 . Futile recanalization is defined as failure of clinical improvement despite successful recanalization and reflects patients in whom there was no or little salvageable ischemic brain tissue by the time revascularization was achieved 35 . Eleven out of twenty-three (47.8%) patients that recanalized in our cohort had a poor outcome. In ProACT II, 26% of patients that recanalized had a poor clinical outcome. The recanalization to favorable outcome mismatch was 45% in IMS, 34% in MERCI and 36% in Multi-MERCI 36 . Several factors have been found to predict clinical outcome after intraarterial therapy for acute stroke including age, baseline stroke severity, extent of hypodensity on baseline non-contrast CT head, hyperglycemia and location of vessel occlusion [35] [36] [37] . Imbalances in these factors likely explain the differences in outcome found between studies. Careful consideration of these factors may help identify patients with the greatest potential to benefit from endovascular therapy and minimize the rate of futile recanalization. Perfusion imaging may further help identify patients with salvageable brain tissue 38 
Limitations
This study has several limitations inherent to its retrospective design. Long term follow up was incomplete and therefore three month or longer follow-up was unavailable. Angioplasty was part of a multimodal intraarterial treatment approach in the majority of patients and, therefore, establishment of reperfusion or adverse effects cannot be attributed to angioplasty alone. Several different operators with variable experience, training background and treatment approaches performed the endovascular procedures in this cohort of patients. It was not possible to evaluate how this might have affected outcome. Differences in patient outcome or response to a specific treatment modality may also relate to clot composition or extent which was not evaluated in this study.
CONCLUSIONS
In this small cohort, an endovascular treatment strategy that employed angioplasty was safe and effectively recanalized acutely occluded intracranial vessels. Angioplasty should be considered as a potential treatment option in interventional acute stroke trials.
